Andrew Huberman· PhD
I think the 2022 New England Journal paper is really fabulous given the different dosages and the comparison to, essentially, what is microdosing and the comparison to citalopram.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think the 2022 New England Journal paper is really fabulous given the different dosages and the comparison to, essentially, what is microdosing and the comparison to citalopram.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
about three months ago a study was published in new england journal medicine which compared psilocybin to lexapro a very very popular commonly used reasonably well tolerated ssri